Oral News and Research

RSS

Young children suffering from diarrheal diseases less likely to receive ORT in private facilities

Young children suffering from diarrheal diseases are less likely to receive life-saving oral rehydration therapy (ORT) if they seek treatment at private, for-profit clinics, according to the first-ever, large-scale study of child diarrhea treatment practices in sub-Saharan Africa.

16 Apr 2014

Viewpoints: Obamacare dilemma -- some people dislike the law but embrace its provisions; are health costs falling?

Polls have consistently shown that even though the public opposes Obamacare, people like some of its most significant provisions. That's particularly true of the requirement that insurers ignore preexisting conditions when signing up customers for coverage.

16 Apr 2014

Dental researchers find new way to study how mouth's natural defenses ward off infection, inflammation

Case Western Reserve University dental researchers have found a less invasive way to extract single rare immune cells from the mouth to study how the mouth's natural defenses ward off infection and inflammation.

16 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

FDA approves Lannett's ANDA for Diazepam Oral Solution

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application (ANDA) for Diazepam Oral Solution (Concentrate), 5 mg/mL, a Schedule C-IV controlled drug.

15 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Prestige Brands Holdings signs agreement for acquisition of Hydralyte

Prestige Brands Holdings, Inc. today announced the signing of a purchase agreement for the acquisition of Hydralyte in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia. The acquisition is expected to close, subject to customary closing conditions, during the first quarter of fiscal 2015, which began on April 1, 2014.

15 Apr 2014

Antibiotics present a safe option for treating children with uncomplicated acute appendicitis

Using antibiotics alone to treat children with uncomplicated acute appendicitis is a reasonable alternative to surgery that leads to less pain and fewer missed school days, according to a pilot study.

15 Apr 2014

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.

15 Apr 2014

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

15 Apr 2014

Radiation plus hormones offers best outcomes for localised prostate cancer

The combination of radiotherapy and androgen deprivation therapy is more effective than radiotherapy alone for preventing disease recurrence in men with localised prostate cancer, according to research findings presented at the European Society for Radiotherapy and Oncology 33rd annual congress in Vienna, Austria.

14 Apr 2014

Study shows link between overuse injury rates in young athletes and their socioeconomic status

A Loyola University Medical Center study is reporting for the first time a link between overuse injury rates in young athletes and their socioeconomic status.

11 Apr 2014

Loyola study reports link between overuse injury rates and socioeconomic status in young athletes

A Loyola University Medical Center study is reporting for the first time a link between overuse injury rates in young athletes and their socioeconomic status.

11 Apr 2014

Inserm plays key role in developing European research

The French National Institute of Health and Medical Research (Inserm) is currently the leading biomedical research organisation in Europe, and plays a key role in developing European research. To mark its 50th anniversary, Inserm wanted to assess the perceptions of Europeans regarding biomedical research.

10 Apr 2014

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China.

10 Apr 2014

Researchers find that cancer gene require copper to promote tumor growth

Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer, researchers at Duke Medicine report.

10 Apr 2014

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection.

10 Apr 2014

Millennium Medical Devices inks another network selling agreement

Millennium HealthCare Inc. today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location.

9 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus.

8 Apr 2014

Oral News and Research

Young children suffering from diarrheal diseases less likely to receive ORT in private facilities

Viewpoints: Obamacare dilemma -- some people dislike the law but embrace its provisions; are health costs falling?

Dental researchers find new way to study how mouth's natural defenses ward off infection, inflammation

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

FDA approves Lannett's ANDA for Diazepam Oral Solution

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Prestige Brands Holdings signs agreement for acquisition of Hydralyte

Antibiotics present a safe option for treating children with uncomplicated acute appendicitis

New drug combination proves effective in treating patients with HCV genotype 1

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Radiation plus hormones offers best outcomes for localised prostate cancer

Study shows link between overuse injury rates in young athletes and their socioeconomic status

Loyola study reports link between overuse injury rates and socioeconomic status in young athletes

Inserm plays key role in developing European research

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Researchers find that cancer gene require copper to promote tumor growth

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Millennium Medical Devices inks another network selling agreement

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Access provides update on new formulation of anti-inflammatory drug amlexanox

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News